Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Canopy Growth CorporationNASDAQ: CGC

Financing Cash Flow · Q4 FY2025 · quarter ended Mar 2026

Financing cash flow turns positive

Q4 FY2025 financing cash flow was CA$46.61M, compared with -CA$15.96M a year earlier. Trailing-twelve-month financing cash flow was CA$366.4M.

Context

  • Financing cash flow amounted to 95.8% of revenue in FY2025, up 40.6 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly financing cash flow holds near CA$46.61M or moves back toward the trailing-twelve-month quarterly average of CA$91.6M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$46.61M-62.8% QoQ
Last fiscal yearMar 2026
CA$463.57M+211.8% YoY
LTMMar 2026
CA$366.4M+146.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+392.1%——
1 year+211.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

CAD · from the cash flow

Latest · FY2025
463.57M CAD
Year-over-year change
+211.8%

Financing Cash Flow vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +146.5% is the 4th highest of 9, against a peer median of +35.2%.
  • Financing cash flow amounts to 117.3% of revenue for CGC, versus a peer median of 12.8%.
CGC Competitors
Financing Cash Flow for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$366.4M CAD+146.5%—117.3%
BIOABioAge Labs, Inc.LTM Mar 2026$136.68M USD-35.4%+66.2%1325.0%
CABACabaletta Bio, Inc.LTM Mar 2026$126.17M USD+2854.7%+44.9%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$102.13M USD+7755.9%+68.0%329441.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.19M USD-29.8%—623.8%
DHDefinitive Healthcare Corp.LTM Mar 2026$51.96M USD-65.2%+78.1%21.8%
ACBAurora Cannabis Inc.LTM Mar 2026CA$9.8M CAD+1152.7%—3.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$5.09M USD——3.8%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$210K USD+100.2%—0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$85K USD-100.6%-75.5%0.2%
Peer median (excluding CGC) —+35.2%+66.2%12.8%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.